A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

CONTEXT: Pazopanib is a small molecule inhibitor of kinases principally including vascular endothelial growth factor receptors-1, -2, and -3; platelet-derived growth factor receptors-α and -β; and c-Kit. We previously reported a tumor response rate of 49% in patients with advanced differentiated thy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bible, Keith C., Suman, Vera J., Molina, Julian R., Smallridge, Robert C., Maples, William J., Menefee, Michael E., Rubin, Joseph, Karlin, Nina, Sideras, Kostandinos, Morris, John C., McIver, Bryan, Hay, Ian, Fatourechi, Vahab, Burton, Jill K., Webster, Kevin P., Bieber, Carolyn, Traynor, Anne M., Flynn, Patrick J., Cher Goh, Boon, Isham, Crescent R., Harris, Pamela, Erlichman, Charles
Format: Artigo
Sprache:Inglês
Veröffentlicht: Endocrine Society 2014
Schlagworte:
Endocrine Care
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010705/
https://ncbi.nlm.nih.gov/pubmed/24606083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-3713
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge